Autoimmunity BioSolutions to Present at the 2025 Sequire Investor Summit in Puerto Rico
Houston, Texas, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Autoimmunity BioSolutions is proud to announce that it will be presenting at...
DNA
Metagenomi Highlights Progress Across Therapeutic Portfolio and Outlines Anticipated Milestones
MGX-001 in Hemophilia A Advances Towards US and Ex-US Regulatory Interactions in 2025 NHP Proof-of-Concept Anticipated for Secreted Protein Deficiency...
Transmission Electron Microscope Market to grow by USD 528.8 Million (2024-2028), driven by focus on nanotechnology, with a report on how AI is reshaping the landscape – Technavio
NEW YORK, Jan. 16, 2025 /PRNewswire/ -- Report with market evolution powered by AI - The global transmission electron microscope market...
Metagenomi Announces New Appointment to its Board of Directors
EMERYVILLE, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing...
Access Healthcare Announces Growth Investment from New Mountain Capital
Investment supports Access Healthcare's plans to accelerate transformation of revenue management for healthcare organizations NEW YORK and DALLAS, Jan. 14,...
Illumina and NVIDIA collaborate to decode biology and propel precision health
Collaboration combines Illumina's sequencing technologies and Illumina Connected Software with NVIDIA tools to develop biological foundation models SAN DIEGO, Jan....
Clinical Trial of NeuroSigma’s Monarch eTNS System for ADHD at King’s College London Completes Enrollment
ATTENS (ADHD trial of external trigeminal nerve stimulation) Project, led by Professor Katya Rubia at the Institute of Psychiatry, Psychology...
Illumina launches pilot proteomics program with UK Biobank and biopharma collaborators to analyze 50,000 samples
Study will generate a key reference data set with Illumina Protein Prep solution SAN DIEGO, Jan. 13, 2025 /PRNewswire/ --...
Cmbio® Acquires Eagle Genomics’ Assets to Enhance Multi-Omics Software and AI/ML capabilities of its Digital Biology Platform.
COPENHAGEN, Denmark, Jan. 10, 2025 /PRNewswire/ -- Cmbio®, a global leader in multi-omics science and digital biology, is pleased to...
Applied DNA Completes Buildout of GMP Facility for LineaDNA IVT Templates
- Signals Start of New Commercialization Phase for LineaRx Subsidiary -- Company Negotiating GMP Supply Agreement -- Company Reaffirms Strategic...
Yerbaé Expands Distribution with Four New Partnerships, Creating Synergies with Safety Shot’s Operations
SCOTTSDALE, Ariz., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Yerbaé Brands Corp. (TSX-V: YERB.U; OTCQX: YERBF) (“Yerbaé” or the “Company”), a...
LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers
LAVA-1266 is a potent and selective bispecific anti-CD123 Gammabody®First-in-human study enrolling adult patients with CD123-expressing AML or MDSInitial Phase 1...
NCCN Guidelines Updated to Include ctDNA-MRD Testing Recommendation for B-Cell Lymphoma
BOULDER, Colo., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Foresight Diagnostics, a leader in ultra-sensitive minimal residual disease (MRD) detection technology,...
Totus Medicines Announces Successful Completion of a Phase 1 Dose-Escalation Study and Initiation of an Expansion Trial Evaluating TOS-358, a Covalent PI3Ka Selective Therapy for the Treatment of Select Solid Tumors and Appoints Zelanna Goldberg as Chief Medical Officer
Successfully completed a Phase 1 dose-escalation study demonstrating pan-mutant clinical activity, 95% target engagement and no grade 3 or 4...
Recludix Pharma to Present at the Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in the discovery of inhibitors of challenging targets...
Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference
Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community penetration Enrolling three Phase...
healthŌme, Inc. Announces Rename and Rebrand as Kadance, Inc.
HUNTSVILLE, Ala., Jan. 9, 2025 /PRNewswire/ -- healthŌme®, Inc., a pioneering genomics-based precision health management company, today announced its renaming...
Onco-Innovations’ Technology Shown in Study to Successfully Inactivate DNA Repair in Cancer, Potentially Boosting Radiation Therapy Effectiveness
VANCOUVER, BC / ACCESSWIRE / January 9, 2025 / Onco-Innovations Limited (CSE:ONCO)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased...
RyboDyn, Inc. Announces Discovery of a Cryptic Human Proteome and $4M Pre-Seed Financing
Dark genome biotech company RyboDyn closes pre-seed fundraise from leading global investors to advance cancer immunotherapy SAN DIEGO, Jan. 9,...
Ginkgo Bioworks Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference
BOSTON, Jan. 9, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity,...